艾社康：健康中国2030-消除丙肝威胁行动白皮书（94页）.pdf

1、?2030?1?2016-2021?2016-2021?“?”?11.11.21.322.12.233.13.23.33.4?122.12.233.13.23.33.43.5?122.12.22.32.42.533.13.23.34?06071417252729334142457486?2?3?4?Hepatitis C?World Health Organization,WHO?7 100?2030?2016?2021?GHSS?2030?2014?2017?2017-2020?2019?3?DDAs?“?”?760?5?2019?12?“?”?2020?2030?“?“?2030?1.?“

2、?203?”?06?7?1.?1.1?HCV?HCV?2-24?15%45%?6?6?HCV?55%85%?20?15%30%?1%3%?8HCV?1?2?3?4?HIV?HIV?HCV?HCV?-HCV?HCV?HCV RNA?HCV?1-2?HCV RNA?50?70?-HCV?78?90?-HCV?-HCV?HCV RNA?-HCV?“?-HCV?”?HCV RNA?HCV RNA?HCV?HCV RNA?HCV?HCV?-HCV?HCV RNA?-HCV?HCV RNA?HCV?7?1-7?1a?1b?HCV?1?1b?1b?3?HCV?1.2?WHO?90%?117?-HCV?3%?

3、1.8?7 100?300-400?HCV?20%?7.4%?9?39.9?WHO?2.3%?1.0%?6.3%?7.0%?4.2%?4.3%?3.3%?2.2%?3.0%?WHO?2016?1.1?10?3.8%?6.4%?2.1%?1?WHO?2015?23.7/10?WHO?2016?1.2 WHO?2015?11?HCV?HCV?-HCV?35%61%?HCV?60%80%?HCV?30?HCV?HCV?1?46.2%?3?30.1%?2?4?6?22.8%?5?1%2?1.3 HCV?12?1?HCV?33%?HCV?1?1.3?-HCV?-HCV?0.43%?1%?760?HCV?

4、HCV?HCV?HCV?HCV?1?-HCV?48.67%?2016?250?120?HCV?2?HIV?HCV?60%90%?70?4060?HIV?HCV?3?-HCV?6.59%?2016?447 435?3?4?-HCV?0.84%3?500?1 000?HCV?13?4?8?5?HCV?-HCV?0.08%0.50%?-HCV?0.09%0.26%?-HCV?0.54%?0.27%?0.40%?0.53%?0.29%?-HCV?50-59?-HCV?0.77%?-HCV?1-4?-HCV?0.09%?HCV 1b?2a?1b?56.8%?2?24.4%?3?3a 7.06%?3b 5

5、.2%?4?5?4?1?45.2%?36.8%?2?3?3?6?3?5?3?3b?3a?5?14?760?HCV?-HCV?HCV?HIV?HCV?Huiying Rao,Lai Wei et al.Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection.?1.4?152.?2.1?WHO?Disability-Adjusted Life Years,DALY?DALY?20?1.5?16?10%1

6、5%?10?80%?10?25%?1?33%6?1990-2010?20?15-49?50-69?DALY?15-49?20?48.70%?DALY?22.4%?50-59?30.14%?DALY?50.79%?20?70?36.74%?50-59?14.29%?20?DALY?61.40%?HCV?2.2?22.51%?3.49%7?2016?HCV?8?1.8?4?8.5?62.9?9.2?2019?39244?14 389?40?2019?100%?100%?300%?200%?500%?17?15?42?25.4?41.23?42.77?9?HCV?3.?DAA?alpha?PR?DA